GlaxoSmithKline to make clinical trial data available to other researchers

Published on October 15, 2012 at 2:39 AM · No Comments

GlaxoSmithKline (GSK) CEO Andrew Witty "said on Thursday detailed data from its clinical trials would be made available to other researchers," Reuters reports, adding, "That would include anonymized patient-level results that sit behind clinical trials of approved and failed drugs" (Hirschler, 10/11). In a speech to the Wellcome Trust in London on Thursday, Witty said that "openness to the public and active collaboration with scientists and firms outside GSK are essential to finding new drugs to treat the diseases plaguing the world, from novel antibiotics to cures for malaria and tuberculosis," the Guardian writes (Boseley, 10/10). "The initiative will enable researchers to examine the data more closely or combine data from different studies to carry out further research and learn more about how medicines work, the company said," according to the Wall Street Journal (Falconi, 10/11).

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post